Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Open-Label Phase IV Clinical Study to Evaluate the Biomarkers, Effectiveness, and Safety Based On A Modified Fixed Dose Regimen of Aflibercept 8mg in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07728981 is registered in ClinicalTrials.gov with Tianjin Medical University Eye Hospital as lead sponsor.

NCT NCT07728981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07728981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Open-Label Phase IV Clinical Study to Evaluate the Biomarkers, Effectiveness, and Safety Based On A Modified Fixed Dose Regimen of Aflibercept 8mg in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Lead sponsor
Tianjin Medical University Eye Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 25, 2026
Completion date
December 31, 2027
Enrollment
49 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd) wet amd